NEW YORK – Immune prognostic tools developer PredictImmune announced Monday an exclusive partnership for diagnostic company Theradiag to promote, license, and distribute the PredictSure IBD test in French-speaking countries in Europe and Africa.
France-based Theradiag, which specializes in in vitro diagnostics and theranostics for autoimmune disease, will lead commercialization in France, Belgium, Luxembourg, Switzerland, and the Maghreb countries in northwest Africa.
Other terms of the deal were not disclosed.
The IBD test, which was commercialized in the United Kingdom and Ireland earlier this year, will be PredictImmune's first product launch in continental Europe. The company recently announced a similar partnership with KSL Biomedical for North American commercialization of the IBD test.
The blood-based biomarker test, which leverages quantitative PCR technology, is meant to provide a preview of future disease outcomes at the point of diagnosis, allowing for better treatment choices earlier in the disease, Cambridge, UK-based PredictImmune said in a statement.